Table 2.
Marker | 14a | 28a | 3b | 7b | 14b | 21b | 28b |
---|---|---|---|---|---|---|---|
CD3 + | |||||||
Group1 | 56.4 ± 4.5 | 61.1 ± 8.6 | 65.6 ± 3.6 | 66.4 ± 5.0 | 57.7 ± 4.7 | 58.7 ± 7.0 | 69.8 ± 7.9 |
Group2 | 51.9 ± 5.6 | 49.0 ± 6.7 | 53.9 ± 6.8 | 59.9 ± 3.9 | 51.8 ± 8.4 | 54.4 ± 5.8 | 58 ± 6.6 |
Group3 | 52.7 ± 3.9 | 49.8 ± 10.9 | 44.76 ± 6.3 | 59.6 ± 8.8 | 61.1 ± 5.2 | 57.2 ± 7.3 | 51.4 ± 8.3 |
Group4 | 50.8 ± 2.1 | 49.8 ± 6.4 | 48.3 ± 7.0 | 52.6 ± 8.7 | 51.8 ± 10.7 | 50.6 ± 9.7 | 52.4 ± 6.8 |
CD4 + | |||||||
Group1 | 18.6 ± 3.4 | 15 ± 4.1 | 9.7 ± 3.8 | 4.6 ± 0.3 | 4.3 ± 4.2 | 1.9 ± 0.6 | 4.1 ± 1.2 |
Group2 | 17 ± 1.2 | 16.5 ± 8.4 | 5.9 ± 2.9 | 5.2 ± 5.4 | 6.3 ± 2.3 | 1.33 ± 0.9 | 4.2 ± 2.5 |
Group3 | 28.7 ± 0.2 | 24.9 ± 8.2 | 11.6 ± 5.5 | 3.1 ± 1.5 | 8.0 ± 5.3 | 20 ± 6.3 | 22.7 ± 2.2 |
Group4 | 23.6 ± 4.3 | 30.7 ± 5.4 | 26.5 ± 3.7 | 32.4 ± 0.2 | 26.3 ± 3.5 | 19.6 ± 2.8 | 23.1 ± 3.3 |
CD8 + | |||||||
Group1 | 30.3 ± 5.3 | 33.3 ± 8.1 | 27.6 ± 6.5 | 64.8 ± 8.2 | 50.7 ± 6.6 | 53.0 ± 9.2 | 46 ± 0.2 |
Group2 | 27.5 ± 5.4 | 35.5 ± 7.3 | 26.4 ± 3.0 | 58.8 ± 9.1 | 48.6 ± 2.0 | 51.8 ± 11.2 | 50.1 ± 4.7 |
Group3 | 28.0 ± 4.5 | 29.1 ± 7.5 | 13.5 ± 2.1 | 24.5 ± 6.2 | 29.7 ± 9.5 | 38.8 ± 3.2 | 30 ± 3.6 |
Group4 | 29.7 ± 6.4 | 32.7 ± 3.0 | 29.3 ± 2.6 | 29.5 ± 8.7 | 30.2 ± 8.9 | 32.4 ± 3.3 | 36.7 ± 0.5 |
CD4 + CD8 + | |||||||
Group1 | 29.4 ± 7.8 | 23.9 ± 8.6 | 32.9 ± 3.1* | 39.1 ± 2.6* | 28.3 ± 7.1 | 25.4 ± 6.5 | 31.4 ± 7.7 |
Group2 | 30.5 ± 4.2 | 21.7 ± 9.7 | 18.3 ± 5.2 | 26.4 ± 4.5 | 17.2 ± 7.4 | 26.0 ± 7.9 | 29.5 ± 3.8 |
Group3 | 18.9 ± 0.1 | 18.5 ± 7.0 | 8.7 ± 3.0 | 7 ± 5.7 | 13.2 ± 1.2 | 19.2 ± 6.9 | 18.1 ± 5.3 |
Group4 | 20.5 ± 4.3 | 22.8 ± 3.1 | 28 ± 4.8 | 26.4 ± 10.2 | 25.7 ± 8.0 | 23.5 ± 6.5 | 28.9 ± 4.1 |
Results are expressed as mean (%) ± SD. Group 1: CH-1R/pIL-4 + Challenged; Group 2: CH-1R + Challenged; Group 3: Challenged; Group 4: Mock. *p < 0.05
aDays post- immunization (DPI); bDays post-challenge (DPC)